Vital Therapies Outlines Plans for New Phase 3 Trial of ELAD(R) in Alcohol-Induced Liver Decompensation
September 28, 2015 at 07:01 AM EDT
Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver ...
